Phase 3 · NCT06859268
TRIUMPH-6
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Retatrutide Treatment in the Maintenance of Weight Reduction in Individuals With Obesity
Active, not recruitingVerified
Registry record
Trial details
- Trial
- TRIUMPH-6
- ClinicalTrials.gov ID
- NCT06859268
- Indication
- Obesity
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 643
- Status
- Active, not recruiting
- Interventions
- Drug: Retatrutide; Drug: Placebo
- Comparator
- Placebo
- Eligible ages
- 18 Years – No maximum
- Locations
- 53 sites · Canada, United Kingdom, United States
- Study start
- 5 Mar 2025
- Primary completion
- 1 Apr 2028
- Study completion
- 1 Apr 2028
Verification
- Last verified
- 4 Sept 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 3 Mar 2026
Endpoints
Primary
Percent Change from Baseline in Body Weight
Secondary
Change from Baseline in Waist Circumference; Percentage of Body Weight Reduction Achieved at Week 80 that is Maintained at Week 116; Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT)